1355. Prophylactic Probiotic Supplementation Decreases the Incidences of NEC, Nosocomial Infections and Mortality in a Newborn Unit: A Prospective Cohort Study
Session: Poster Abstract Session: Clinical Trials
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
Background: To observe if there is any difference regarding the incidences of NEC, mortality and nosocomial infections between the groups receiving prophylactic enteral probiotic supplementation or not in a neonatal intensive care unit (NICU).

 

Methods: The records of neonates (>1000 gr) who received routine supplementation of probiotics (Bifidobacterium animalis, Streptococcus thermophilus) for 6 months were compared with the neonates within the same NICU who did not receive probiotics for previous 6 months. The incidences of NEC, nosocomial infections and mortality were prospectively followed after receiving approval of ethics committee. There were 119 neonates who did not receive probiotic supplementation and 78 who received making a total of 197 subjects. We used Fisher’s exact test for analysis. 

 

Results: We observed 6 prematures with NEC (6/119, %5) in cohort group who did not receive probiotic whereas no subject was diagnosed as NEC (0/78) in probiotic group (p:0.044). The rate of nosocomial infection was 17/78 (%21.8) in probiotic group whereas it was 41/119 (%34,45) in the cohort group, and it was significantly lower in probiotic group (p:0.039). There was also decrease in density of nosocomial infections in probiotic group 14,02/1000 days when compared with cohort group with the density of 22.55/1000 days (p:0.054), but insignificant. There was no statistically significant difference in terms of hospital stay between the groups. We observed statistically significant decrease in mortality between groups. Mortality rate was %2,56 (2/78) in probiotic group whereas %10,08 (12/119) in neonate group who did not receive prophylaxis (p:0.037).    

 

Conclusion: We observed statistically significant decrease in the incidences of NEC and mortality between the groups who received probiotics and not. This finding is parallel with recently published meta-analyses reporting that prophylactic probiotic administration prevents NEC and its complications in neonates. In this study, we also observed a reduction in nosocomial infection rate significantly (including NEC) but borderline significance in incidence density. Certainly, we need more studies to define whether prophylactic probiotics prevent nosocomial infections and its complications in NICU.

Metehan Ozen, Professor1, Abdulkerim Elmas1, Ahmet Rifat Ormeci2 and Ener C. Dinleyici, MD3, (1)Pediatrics, Suleyman Demirel University, ISparta, Turkey, (2)Suleyman Demirel University, ISparta, Turkey, (3)Department of Pediatric Intensive Care and Infectious Disease Unit, Eskisehir Osmangazi University, Faculty of Medicine, Eskisehir, Turkey

Disclosures:

M. Ozen, Pfizer Consumer Health: Speaker's Bureau, Speaker honorarium

A. Elmas, None

A. R. Ormeci, None

E. C. Dinleyici, Biocodex: Speaker's Bureau, Speaker honorarium

See more of: Clinical Trials
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.